On this episode, broadening of immune responses to SARS-CoV-2 after mRNA vaccine booster to ChAdOx1 nCoV-19, five-fold underestimation of the number of cases in the US during the first six months of the pandemic, and a monoclonal antibody that broadly neutralizes many different sarbecoviruses.
TWiV discusses the finding that the envelope (E) protein of SARS-CoV-2 is sensed by toll-like receptor 2 on cells, leading to the production of inflammatory cytokines that cause damage to cells and tissues in COVID-19.
TWiV explains why hydroxychloroquine failed in humans despite showing antiviral effects in cells, and reviews the published data on the Pfizer/BioNTech mRNA vaccine.
TWiV answers listener questions about pandemic response, excess deaths in 25-44 year olds, vaccines, vaccines, and vaccines.
Daniel Griffin provides his weekly clinical report on COVID-19, including his own experience with vaccination, guidelines for vaccine distribution, reasons for under-utilization of monoclonal antibody therapy, and much more.
TWiV explains that COVID-19 is not harmless for young adults, FAA approval for Pfizer mRNA vaccine, lack of justification for the claim of reverse transcription of SARS-CoV-2 RNA and integration into the human genome, and lack of evidence for increased transmission by new variants in the UK.
Daniel Griffin provides his weekly clinical report on COVID-19, including thoughts on the first immunizations with Pfizer mRNA vaccine, the anticipated EUA for the Moderna vaccine, whether the vaccine prevents infection, not just disease, monoclonal antibody therapy, and much more.
On this episode, TWiV makes Bloomberg Business News 2020 Jealousy List, crushing of CDC revealed by insiders, seasonal influenza during the COVID-19 pandemic, FDA briefing documents from Moderna, and three-quarters attack rate of SARS-CoV-2 during an unmitigated epidemic in Brazil.
On this episode, FDA EUA for Pfizer mRNA vaccine, efficacy of AstraZeneca ChAdOx1 COVID-19 vaccine, and an orally administered drug that blocks SARS-CoV-2 transmission in ferrets.
The TWiVers analyze efficacy of the AstraZeneca/Oxford adenovirus vectored vaccine, SARS-CoV-2 did not infect miners who became ill 8 years ago after cleaning bat guano from a cave in Yunnan Province, and induction of antigen-specific germinal center responses and production of neutralizing antibody by SARS-CoV-2 mRNA vaccine but not purified protein.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.